Histone deacetylase 3 overexpression in human cholangiocarcinoma and promotion of cell growth via apoptosis inhibition

Clinical presentation, risk factors and staging systems of cholangiocarcinoma

(2015) Ruben R. Plentz et al.   BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY

Ku80 cooperates with CBP to promote COX-2 expression and tumor growth

(2015) Yao Xiao et al.   Oncotarget

A novel class I HDAC inhibitor, MPT0G030, induces cell apoptosis and differentiation in human colorectal cancer cells via HDAC1/PKCδ and E-cadherin

(2015) Li-Ting Wang et al.   Oncotarget

New and emerging HDAC inhibitors for cancer treatment

(2014) Alison C. West et al.   JOURNAL OF CLINICAL INVESTIGATION

Pathogenesis, Diagnosis, and Management of Cholangiocarcinoma

(2013) Sumera Rizvi et al.   GASTROENTEROLOGY

Incidence and mortality trends for biliary tract cancers in Austria

(2013) Matthias Pinter et al.   LIVER INTERNATIONAL

HDAC5—A Critical Player in the p53 Acetylation Network

(2013) Sam Sulgi Kim et al.   MOLECULAR CELL

HDAC3-selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner

(2013) M. Malvaez et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Induction of differentiation and apoptosis in leukaemic cell lines by the novel benzamide family histone deacetylase 2 and 3 inhibitor MI-192

(2012) Marjorie Boissinot et al.   LEUKEMIA RESEARCH

Histone deacetylases and cancer

(2012) Bruna Barneda-Zahonero et al.   Molecular Oncology

Histone deacetylases are dysregulated in rheumatoid arthritis and a novel histone deacetylase 3-selective inhibitor reduces interleukin-6 production by peripheral blood mononuclear cells from rheumatoid arthritis patients

(2011) Justin Gillespie et al.   ARTHRITIS AND RHEUMATISM

Epigenetic-Based Therapies in Cancer

(2011) Sang-Hyun Song et al.   DRUGS

Epidemiological trends in incidence and mortality of hepatobiliary cancers in Germany

(2011) Thomas von Hahn et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

HDACs and HDAC inhibitors in colon cancer

(2010) John M. Mariadason   Epigenetics

The role of histone deacetylase 7 (HDAC7) in cancer cell proliferation: regulation on c-Myc

(2010) Caihua Zhu et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

High-Precision Radiosurgical Dose Delivery by Interlaced Microbeam Arrays of High-Flux Low-Energy Synchrotron X-Rays

(2010) Raphaël Serduc et al.   PLoS One

HDAC inhibitor-based therapies and haematological malignancy

(2009) L. Stimson et al.   ANNALS OF ONCOLOGY

JNJ-26481585, a Novel "Second-Generation" Oral Histone Deacetylase Inhibitor, Shows Broad-Spectrum Preclinical Antitumoral Activity

(2009) J. Arts et al.   CLINICAL CANCER RESEARCH

Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

(2009) Richard L. Piekarz et al.   JOURNAL OF CLINICAL ONCOLOGY

HDAC family: What are the cancer relevant targets?

(2008) Olaf Witt et al.   CANCER LETTERS

HDAC4 represses p21WAF1/Cip1 expression in human cancer cells through a Sp1-dependent, p53-independent mechanism

(2008) D Mottet et al.   ONCOGENE